sridevirajeeve Profile Banner
Sridevi Rajeeve, MD Profile
Sridevi Rajeeve, MD

@sridevirajeeve

Followers
2K
Following
8K
Media
84
Statuses
1K

⚕️Asst. Attending Myeloma & Cell Therapy @MSKCancerCenter via @MountSinaiNYC @TischCancer 🇮🇳➡️🇺🇸 Interests: #MMsm #CART #cellulartherapy

New York, NY
Joined August 2009
Don't wanna be here? Send us removal request.
@sridevirajeeve
Sridevi Rajeeve, MD
3 years
Amazing evening receiving the @ASCO @ConquerCancerFd Young Investigator Award (YIA) 2022. Thankful to my stellar mentor Dr. Samir Parekh at @IcahnMountSinai & @TischCancer @SinaiHemeOnc for the support! #ASCO22 📸3: friends, old and new @drsomedeb 📸4: proud hubby @suchithnair
10
3
98
@FrancescoMaura4
Francesco Maura
1 day
Excited to share new study out today on @JCO_ASCO where we leveraged #WGS to reclassify MGUS and SMM and define the concept of "malignant transformation" @MSKCancerCenter @LaStatale @MDAndersonNews @MoffittNews @SylvesterCancer @nyulangone @sangerinstitute @MayoClinic #mmsm 1/14
7
35
77
@Myeloma_Doc
Robert Z. Orlowski
3 days
#Myeloma Paper of the Day: AURIGA subgroup analysis finds dara/len maint in NDMM -> higher MRD (10-5) conversion @ 12 mos in original high-risk (31.8 vs 6.7%), revised (43.8 vs 13.3%) & modified IMS 2024 (41.2 vs 0%) & ultra-high-risk (54.5 vs 0%): https://t.co/0AEbUmNJZ2. #mmsm
2
11
29
@sridevirajeeve
Sridevi Rajeeve, MD
2 days
Following an exciting #IMS25, looking forward to synthesizing data across all #PlasmaCellDisorders for the 2nd Annual Kyle-Barlogie Symposium by @MayoClinic & @MSKCancerCenter. 📍 Minneapolis 📅October 10-11, 2025! Link: https://t.co/zDvs1a8A8C 📢Trainees: Complimentary reg!
@VincentRK
Vincent Rajkumar
6 days
I’ll be speaking at this meeting next week. Also speaking are @szusmani @FrancescoMaura4 @UrviShahMD @sridevirajeeve @LesokhinMD and more from @MSKCancerCenter And many of my colleagues from @MayoClinic including @MorieGertz @ADispenzieri @myelomaMD @JoselleCookMD
0
3
7
@RahulBanerjeeMD
Rahul Banerjee, MD, FACP
21 days
#IMS25 Kudos to @andrew02114 for presenting Alliance trial on the big stage at @Myeloma_Society plenary! 👏 Len 15mg (not 25mg) in this older ASCT-ineligible patient population. Addressing mismatch between trials & RW practice by implementing the latter into the former!
1
6
34
@Rfonsi1
Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽
21 days
D. Chenxing Du presenting at plenary session BCMA CART for primary plasma cell leukemia. Impressive results, though small numbers #IMS2025 #mmsm
0
3
8
@sridevirajeeve
Sridevi Rajeeve, MD
21 days
#IMS25 Oral abstract session: results from the TANDEMM trial at @MSKCancerCenter by Dr. Sham Mailankody, presented by @szusmani. In heavily preTx RRMM, co-infusion of BCMA+GPRC5D CART as a dual agent targeting strategy was feasible, tolerable and efficacious. @MSK_DeptOfMed
0
11
23
@sridevirajeeve
Sridevi Rajeeve, MD
22 days
#IMS25 ALC spikes post CART may portend DNTs (ALC >2.4) and Parkinsonism (ALC >3.9) but have no impact on efficacy. Key data that may help harmonize post CART ALC measurements and time points, including advising on interventions to mitigate and prevent DNTs! (⏩CITADEL trial)
0
3
10
@RahulBanerjeeMD
Rahul Banerjee, MD, FACP
22 days
🎵 TACI’s back, alright! Excellent #IMS25 by Puliafito @NoopurRajeMD @MJFzeta et al … using APRIL as CAR (binds both BCMA & cousin TACI) worked well here even in prior BCMA CAR-T failure. Prior @DrRakeshPopat study of APRIL CAR had low ORR - looking forward to learning more!
2
6
12
@sridevirajeeve
Sridevi Rajeeve, MD
22 days
#IMS25 Phase 1 data from the TriPRIL CAR-T (dual targeting BCMA-TACI using natural ligand trimeric APRIL) from MGH showing 80% ORR in a real-world like pt pop (preTx, prior BCMA✅), no new safety signals and (so far) no NINS. Good use case of retargeting BCMA (after 6m break)!
1
5
13
@sridevirajeeve
Sridevi Rajeeve, MD
22 days
#IMS25 Important summary slide on CAR+ T-cell lymphomas from the Immunotherapy session by @BenjaminPuliaf1. Comprehensive workup is needed for all post CART toxicities, especially unusual signs and symptoms, given the heterogeniety of T-cell lymphoma manifestations.
0
4
13
@sridevirajeeve
Sridevi Rajeeve, MD
22 days
#IMS25 Late breaking abstract presented by @CohenAd_MMdoc of STEM study - fixed duration cevostamab consolidation following BCMA CAR-T: tolerable, and with 1y CR rate >90%. Long term f/u data will advise durability of this deep response but can consider, esp in #HRMM!
0
6
9
@mtmdphd
Mike Thompson, MD, PhD, FASCO
27 days
Revised Definition of Free Light Chains in Serum and Light Chain Monoclonal Gammopathy of Undetermined Significance: Results of the iStopMM Study [Dec 10, 2023] Long et al. #ASH23 Abst 535 https://t.co/PZKnY2Fq3v #mmsm #geriheme
0
4
23
@mtmdphd
Mike Thompson, MD, PhD, FASCO
27 days
New Definition of Light Chain Monoclonal Gammopathy of Undetermined Significance [MGUS] [May 29, 2025] Long et al. @sykristinsson @JAMAOnc https://t.co/TDE6QUWfoP #mmsm #geriheme
0
2
12
@mtmdphd
Mike Thompson, MD, PhD, FASCO
4 months
Guidelines for the testing and reporting of cytogenetic results for risk stratification of multiple myeloma: a report of the Cancer Genomics Consortium Plasma Cell Neoplasm Working Group [Jun 18, 2025] Lu et al. @lbaughn @BloodCancerJnl https://t.co/lCE7EDugND #mmsm #hemepath
2
12
29
@FrancescoMaura4
Francesco Maura
4 months
Happy to share our new work out today on @BloodPortfolio #Blood where we report CD38 loss as recurrent mechanisms of resistance to anti-CD38 antibody in multiple myeloma. Great collaboration between @MSKCancerCenter @MSK_DeptOfMed @UCalgary @HDMyeloma @MayoClinic #mmsm #wgs
3
18
49
@VincentRK
Vincent Rajkumar
5 months
We call for a paradigm shift in development of immunotherapy drugs, especially bispecifics. @LeukemiaJnl These drugs have therapeutic effects that last a long time. We need to reduce frequency and switch to limited duration treatment to avoid toxicity. https://t.co/w9Cj9Kqx8U
nature.com
Leukemia - Time for a paradigm shift in immunotherapy-based BCMA/CD3 bispecific drug development in multiple myeloma
2
32
96
@parkerici
Parker Institute for Cancer Immunotherapy
5 months
Early results in patients who had failed prior CAR T: → 81% overall response → 52% complete remission at 3 months → 3-day manufacturing turnaround This research from @carlhjune and team represents the first IL-18–secreting CAR T tested in blood cancer — and it may reshape
@parkerici
Parker Institute for Cancer Immunotherapy
5 months
For patients with lymphoma that relapses after CAR T, clinical options become vanishingly few. Now, a new study in @NEJM led by @carlhjune, Director of the PICI Center @PennMedicine, offers a new approach: huCART19-IL18 –– an IL-18–secreting, “armored” CAR T-cell.
0
12
41
@DAVAOnc
DAVA Oncology
6 months
Dr. @RahulBanerjeeMD from @fredhutch talks on #Cevostamab: A “third-party candidate” in myeloma? ✅ FcRH5 target, maintained post-BCMA exposure ✅ Manageable safety, fewer infections vs. BCMA bsAbs ✅ No GPRC5D toxicities ⏳ Needs better efficacy/durability! #DAVAWhistler
1
9
19
@sridevirajeeve
Sridevi Rajeeve, MD
7 months
Looking forward to the inaugural #iwGPRC5D International Workshop on GPRC5D-Targeted Myeloma Therapies on March 22 in NYC! https://t.co/WcXWhyk1sW Excited to learn & share our collective knowledge on the next frontier beyond BCMA. @szusmani @ShamMailankody @NoopurRajeMD ...
0
6
12
@RahulBanerjeeMD
Rahul Banerjee, MD, FACP
8 months
So excited!! Welcome @UrviShahMD to @fredhutch Grand Rounds. I’m glad you joined by Zoom since shockingly it is raining today in Seattle for the first time in 2 weeks :) Cc @MSKCancerCenter @szusmani @sridevirajeeve @GunjanLShah @MScordoMD #MMsm
0
5
42